Scoreboard / UTHR
United Therapeutics Corporation UTHR
Week of September 24 to October 1, 2026 · Updated October 2, 2026
Setup Snapshot
The Setup in One Card
How UTHR scored, how it moved against the market, and the catalyst behind the move. A high score means the stock deserves research time, not that it is a buy.
Friday Five Score
Weekly Rank
03 of 5
Sector Trend
Laggingdown 2.2 percent
Actionability
News Spike
Catalyst
Patent RulingA Delaware district court found on September 30 that a competitor infringes two claims of the inhaled treprostinil patent.
Returns are measured from the Thursday, September 24 close to the Thursday, October 1 close. Benchmarks: S&P 500 -0.5% and Nasdaq Composite -0.3% for the week. Benchmark figures are official index closes; sector figures use SPDR sector ETF closes because the official S&P sector index closes for this window were not yet published at press time.
Why It Moved
The Story Behind the Move
Catalyst
On September 30 the United States District Court for the District of Delaware found that Liquidia Technologies infringes claims 1 and 14 of United States Patent No. 11,826,327, covering a method of improving exercise capacity in patients with pulmonary hypertension associated with interstitial lung disease by inhaling treprostinil. United Therapeutics said it believes it is entitled to an order instructing the Food and Drug Administration to withdraw approval of the competing product and intends to seek damages including a royalty on past sales. The shares rose 12.5 percent that session and 5.4 percent the next.
Why It Mattered
A court ruling is the most literal form of proof a market can be handed, and the alternatives rule out cleanly: the Food and Drug Administration filing acceptance and the accelerated buyback that also circulated were both announced in early September, before this measurement window opened. A 21 percent move in a sector that fell 2.16 percent is about as company specific as a week gets.
Risk Note
A district court opinion is not a final judgment. The remedy has not been set, whether the Food and Drug Administration is actually instructed to withdraw the competing approval has not been decided, and an appeal is available. The load bearing sentence is the company stating what it believes it is entitled to, which is a litigation position rather than an order.
Reader Takeaway
Legal outcomes get priced as if they are final the day they are announced, and they are usually one step in a longer process. Read what the court actually decided, then read separately what the company says that entitles it to.
Continue the Research
Put UTHR Back in Context
The stock page is one piece of the weekly research. Continue with the original issue, the full public ranking, or the method behind the analysis.
This page is for educational and informational purposes only. It is not financial advice, investment advice, or a recommendation to buy or sell any security.